| Literature DB >> 22460071 |
Kaharu Sumino1, Jennifer Tucker, Muhammad Shahab, Katy F Jaffee, Cynthia M Visness, James E Gern, Gordon R Bloomberg, Michael J Holtzman.
Abstract
BACKGROUND: Viral respiratory tract infections are the leading cause of acute illness during infancy and are closely linked to chronic inflammatory airway diseases later in life. However, the determinants of susceptibility to acute respiratory tract infections still need to be defined.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22460071 PMCID: PMC3340511 DOI: 10.1016/j.jaci.2012.02.033
Source DB: PubMed Journal: J Allergy Clin Immunol ISSN: 0091-6749 Impact factor: 10.793
Baseline demographics and 1-year outcomes of the study population
| Characteristics (n = 82) | |
|---|---|
| Baseline demographics | |
| Female sex, no. (%) | 46 (56) |
| Age (y) of mother at delivery, mean ± SD | 23.7 ± 5.6 |
| Gestational age (wk) at delivery, mean ± SD | 38.4 ± 1.4 |
| Baby's race/ethnicity, no. (%) | |
| Hispanic | 2 (3) |
| African American | 70 (85) |
| Mixed (>1 race/ethnicity) | 10 (12) |
| Parent with asthma, no. (%) | 52 (63) |
| Parent with hay fever, no. (%) | 47 (64) |
| Mother smoked during the first year of life, no. (%) | 33 (44) |
| 1-y Outcomes | |
| No. of colds reported, mean ± SD | 4.2 ± 2.7 |
| No. of wheezing illnesses reported, mean ± SD | 1.3 ± 1.7 |
| ≥2 Wheezing episodes, no. (%) | 20 (27) |
| Any hospitalization, no. (%) | 11 (15) |
| Hospitalization for respiratory tract illness, no. (%) | 6 (8) |
| Hospitalization for wheeze, no. (%) | 2 (3) |
| Ear infection reported, no. (%) | 28 (37) |
Characteristics of the group included in the present study compared with the group that was not included
| Subjects' characteristics | Subjects in the analysis group (n = 82) | Subjects not in the analysis group (n = 96) | |
|---|---|---|---|
| Baseline demographics | |||
| Female sex, no. (%) | 46 (56) | 46 (48) | .28 |
| Age of mother (y) at delivery, mean ± SD | 23.7 ± 5.6 | 23.9 ± 5.2 | .66 |
| Gestational age (wk) at delivery, mean ± SD | 38.4 ± 1.4 | 38.4 ± 1.5 | .71 |
| Baby's race/ethnicity, no. (%) | .22 | ||
| Hispanic | 2 (3) | 2 (2) | |
| African American | 70 (85) | 87 (91) | |
| Mixed (>1 race/ethnicity) | 10 (12) | 5 (5) | |
| Parent with asthma | 52 (63) | 48 (50) | .43 |
| Parent with hay fever | 47 (64) | 42 (49) | .06 |
| Mother smoked during first year of life | 33 (44) | 43 (38) | .58 |
| 1-y Outcomes | |||
| No. of colds reported, mean ± SD | 4.2 ± 2.7 | 3.9 ± 2.9 | .48 |
| No. of wheezing illnesses reported, mean ± SD | 1.3 ± 1.7 | 1.5 ± 2.2 | .58 |
| ≥2 Wheezing episodes, no. (%) | 20 (27) | 28 (32) | .50 |
| Any hospitalization | 11 (15) | 18 (20) | .35 |
| Hospitalization for respiratory tract illness | 6 (8) | 7 (8) | .97 |
| Hospitalization for wheeze | 2 (3) | 1 (1) | .46 |
| Ear infection reported | 28 (37) | 40 (45) | .32 |
Viruses detected in nasal samples during symptomatic episodes and the 12-month scheduled visit
| Virus detected | Symptomatic (n = 38) | Scheduled visit (n = 64) |
|---|---|---|
| Rhinoviruses | 31.6% (12) | 23.4% (15) |
| Adenovirus | 5.3% (2) | 6.3% (4) |
| RSV | 7.9% (3) | 3.1% (2) |
| Coronaviruses | 2.6% (1) | 1.6% (1) |
| Enterovirus | 2.6% (1) | 3.1% (2) |
| Parainfluenza | 2.6% (1) | 1.6% (1) |
| Influenza | 2.6% (1) | 0% (0) |
| Metapneumovirus | 2.6% (1) | 0% (0) |
| Bocavirus | 0% (0) | 1.6% (1) |
| Multiple viruses | 15.8% (6) | 7.8% (5) |
| Virus detected | 73.7% (28) | 48.4% (31) |
Values in parentheses indicate numbers of patients.
More than 1 respiratory tract virus detected.
Distribution of antiviral responses among subjects
| Distribution of antiviral responses | No. | Median | IQR |
|---|---|---|---|
| 72 | 6.21 | 3.09-14.74 | |
| 71 | 0.97 | 0.34-1.94 | |
| RSV RNA copy number | 70 | 213,918 | 137,872-436,690 |
| STAT1 phosphorylation with IFN-β | 63 | 6.17 | 2.79-11.72 |
Definition of antiviral responses: CCL5 mRNA response to RSV = CCL5 mRNA copies with RSV/CCL5 mRNA copies without RSV, IFNG mRNA response to RSV = IFNG mRNA copies with RSV/IFNG mRNA copies without RSV, RSV RNA copy number = RSV RNA copy number with RSV infection–Without infection, STAT1 phosphorylation with IFN-β = (P-STAT1 with IFN-β/Total STAT1 with IFN-β)/(P-STAT1 without IFN-β/Total STAT1 without IFN-β).
IQR, Interquartile range.
Fig 1Association of antiviral responses at birth with the number of upper respiratory tract infections (colds) and wheezing episodes in the first year of life. A, The antiviral response of cord blood monocyte cultures was monitored by using RSV-induced increases in CCL5 mRNA (n = 65), IFNG mRNA (n = 66), and RSV RNA (n = 63) and using IFN-β–dependent increases in STAT1 phosphorylation (n = 57). The relationship of these values to the reported occurrences for upper respiratory tract infections and wheezing episodes were analyzed by using the Spearman rank correlation coefficient. *Significant inverse correlation. B, For conditions in Fig 1, A, the individual values for RSV induction of IFNG mRNA and the number of colds (n = 66). C, For conditions in Fig 1, A, analysis of the mean values for RSV induction of IFNG mRNA in relation to low, medium, or high number of reported colds (n = 66).
Fig 2Relationship of RSV induction of IFNG mRNA to the occurrences of ear infections (n = 25/66), croup (n = 6/66), sinus infections (n = 9/66), pneumonia (n = 4/66), and respiratory hospitalizations (n = 6/66) in the first year of life. There were no reported cases of stomach flu. The IFNG mRNA response to RSV infection was determined as described in the legend for Fig 1. The boxes represent the median (middle line) and interquartile range, and the whiskers extend out to show extreme values. Potential outliers are plotted as the dashed lines outside the whiskers. These are shown for groups without (No) and with (Yes) the indicated clinical condition.